Get the latest Science News and Discoveries
Neoadjuvant dual immuno-combination therapy with anti-LAG3 and anti-PD-1 antibodies is feasible and safe for resectable non-small cell lung cancer - EurekAlert!
Comprehensive up-to-date news coverage, aggregated from sources all over the world by Google News.
None
Or read this on Eureka Alert